As previously reported, Benchmark upgraded Codexis to Buy from Hold with a $9 price target after the company reported what the firm calls “positive financial results” for Q4 that beat the firm’s estimates. Management also provided guidance for $56M-$64M in revenues for 2024, up 10%-15% from 2023 excluding COVID, notes the analyst, who cites the “strong fourth quarter results and positive guidance going forward” for the raised rating.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CDXS:
- Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
- Codexis, Roche in licensing deal for newly engineered double-sranded DNA Ligase
- Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche
- Codexis to Participate in TD Cowen 44th Annual Health Care Conference
- CDXS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
